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Background: The evolutionarily conserved DNA mismatch repair (MMR) system corrects base-substitution and
insertion-deletion mutations generated during erroneous replication. The mutation or inactivation of many MMR
factors strongly predisposes to cancer, where the resulting tumors often display resistance to standard chemotherapeutics.
A new direction to develop targeted therapies is the harnessing of synthetic genetic interactions, where the simultaneous
loss of two otherwise non-essential factors leads to reduced cell fitness or death. High-throughput screening in human
cells to directly identify such interactors for disease-relevant genes is now widespread, but often requires extensive
case-by-case optimization. Here we asked if conserved genetic interactors (CGIs) with MMR genes from two
evolutionary distant yeast species (Saccharomyces cerevisiae and Schizosaccharomyzes pombe) can predict
orthologous genetic relationships in higher eukaryotes.
Methods: High-throughput screening was used to identify genetic interaction profiles for the MutSα and MutSβ
heterodimer subunits (msh2Δ, msh3Δ, msh6Δ) of fission yeast. Selected negative interactors with MutSβ (msh2Δ/msh3Δ)
were directly analyzed in budding yeast, and the CGI with SUMO-protease Ulp2 further examined after RNA
interference/drug treatment in MSH2-deficient and -proficient human cells.
Results: This study identified distinct genetic profiles for MutSα and MutSβ, and supports a role for the latter in
recombinatorial DNA repair. Approximately 28% of orthologous genetic interactions with msh2Δ/msh3Δ are
conserved in both yeasts, a degree consistent with global trends across these species. Further, the CGI between
budding/fission yeast msh2 and SUMO-protease Ulp2 is maintained in human cells (MSH2/SENP6), and enhanced
by Olaparib, a PARP inhibitor that induces the accumulation of single-strand DNA breaks. This identifies SENP6
as a promising new target for the treatment of MMR-deficient cancers.
Conclusion: Our findings demonstrate the utility of employing evolutionary distance in tractable lower
eukaryotes to predict orthologous genetic relationships in higher eukaryotes. Moreover, we provide novel
insights into the genome maintenance functions of a critical DNA repair complex and propose a promising
targeted treatment for MMR deficient tumors.* Correspondence:
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Defective DNA mismatch repair (MMR) is the underlying
cause of hereditary non-polyposis colorectal cancer/Lynch
syndrome (HNPCC/LS) and a significant proportion of
sporadic colorectal cancers (CRCs) [1,2]. The MMR genes
most frequently mutated or epigentically silenced in these
cancers are MSH2 and MLH1, which respectively function
in the coordination of mismatch recognition and excision
[3,4]. The characteristic repair steps in MMR are highly
conserved in bacteria, yeast, and mammals. In eukaryotes,
the efficient recognition of distinct mismatches requires
subsets of three different homologs of bacterial mutS: the
MutSα heterodimer (MSH2-MSH6) initiates the repair of
single-base mispairs and single-base insertion/deletions
(IDLs), while MutSβ (MSH2-MSH3) primarily initiates
the repair of larger IDLs of two to four bases but also
facilitates the restoration of single-base mismatches [5]
(Figure 1A). Subsequent to mismatch recognition MutSα
or MutSβ interact with MutLα (MLH1-PMS2) in anFigure 1 Synthetic lethality as a therapeutic strategy for the treatmen
process. In the schematic the MutSα heterodimer (Msh2-Msh6) recognizes
exclusively [6-9]) initiates the repair of larger insertions/deletions (IDLs) of t
(Mlh1-Pms2) and multiple downstream factors (for example, Exo1, PCNA, R
resynthesis. Each MutS also has roles independent of these downstream effec
at sites of DNA damage to mediate arrest and apoptosis [3], while MutSβ
single-strand annealing [10,11]. Mutations in many factors from this pathw
common initiating event in many colorectal cancers. Candidate screening
sick/lethal) to selectively kill cells that harbor the MSH2 deficiency, but spaATP-dependent manner to initiate excision of the appro-
priate DNA strand [3]. During this process individual
MutS and MutL subunits directly interact with PCNA,
RFC, and RPA, indicating that mismatch excision is
closely correlated with DNA replication [3].
As a consequence of their defective MMR, HNPCC/
LS tumors and sporadic CRCs display increased rates of
replication errors at short repeat sequences, termed
microsatellite instability (MSI). MSI-positive tumors
exhibit resistance to DNA damaging agents, and thus
respond poorly to conventional chemotherapy [12,13].
Of additional concern, the treatment of these patients
with chemotherapeutic agents can induce secondary
therapy-related leukemias (for example, acute myeloid
leukemia/myelodysplastic syndrome) [14,15]. Indeed it has
been suggested that the primary treatment of HNPCC/LS
with chemotherapeutics actually selects for hematopoietic
precursor cells with MMR-defects [16]. As these cells
proliferate they accumulate further mutations and developt of MMR-deficient cancers. (A) DNA mismatch repair is a stepwise
a single-base mispair while MutSβ (Msh2-Msh3) primarily (but not
wo to four bases. Recognition activates the recruitment of MutLα
FC, RPA, and DNA pol δ) for repair by lesion excision and strand
tors of MMR: as an example, MutSα associates with cell cycle regulators
contributes to the repair of double-strand breaks via recombinatorial
ay are associated with cancer. (B) Loss of A (for example, MSH2) is a
seeks to identify and exploit negative genetic relationships (synthetic
re those lacking this cancer-related alteration.
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opment of novel therapeutic strategies that efficiently and
selectively target the primary MMR-deficient cancer but
avoids therapy-induced secondary tumors would be highly
desirable.
A promising new direction to develop targeted therapies
is the harnessing of synthetic genetic interactions, where
the simultaneous loss of two otherwise non-essential
factors leads to reduced cell fitness (synthetic sickness
(SS)) or cell death (synthetic lethality (SL)) [17,18]. This
provides great functional insight: an SS/SL interaction
for two alleles often indicates that their gene products
are in parallel pathways or impinge on the same essen-
tial function. However it can also provide an elegant
strategy to selectively eliminate tumor cells that harbor
specific cancer-causing mutations. In this manner, the
protein products of genes SS/SL to cancer-causing mu-
tations represent potential drug targets (Figure 1B). As
an example, inhibitors of poly-ADP-ribose polymerase I
(PARP; required for the repair of single-stranded DNA
breaks) are lethal to cells with deficiencies in BRCA1 or
BRCA2 and show promise in the treatment of breast
cancer [19,20].
A range of approaches can be used to search for SS/SL
interactions with therapeutic intent, the most direct being
RNA interference-based screening by si/shRNA libraries
in human cells [21,22]. Although RNAi lends itself to
high-throughput, incomplete knockdowns or off-target
effects are commonly observed, and the large scale-
format precludes single-case optimization. There are
additional issues related to cost, that robotic sample
handling might limit the type of read-out assay, the
requirement for easily transfectable cell-lines, and even
the possibility that an SS/SL interaction might be cell-
type specific. Despite these potential concerns, various
studies describe the successful application of high-
throughput RNAi-based approaches to investigate
mammalian gene function [21-24]. Indeed recent ana-
lyses identified the synthetic combinations MSH2/DNA
pol β, MLH1/DNA pol γ, and MSH2/dihydrofolate reduc-
tase [25,26]. This directly demonstrates the existence of
SS/SL interactions for mammalian MMR genes, although
both DNA polymerases are essential in knockout mice
and contribute to high-fidelity replication in dividing cells
[27,28], which may limit their potential as therapeutic
targets.
Genetic interaction screening in tractable model or-
ganisms constitutes a powerful alternative approach for
candidate identification. Defining the function of a gene
product in budding and fission yeasts (Saccharomyces
cerevisiae (Sc) and Schizosaccharomyces pombe (Sp), re-
spectively) has proven highly predictive of the role of its
metazoan ortholog [29,30]. These yeasts separated ap-
proximately 380 million years ago [31] (by comparison,the last common predecessor of the entire mammalian
class existed about 165 mya [32]), but share substantial
gene content, with approximately 75% of Sp genes having
one or more Sc orthologs [33-35]. This high level of con-
servation commonly extends to functional units, such that
many yeast complexes are reminiscent of their metazoan
counterparts [36,37]. High-throughput genetic interaction
mapping approaches have been developed for both yeasts
to evaluate the genetic interactions of null, hypomorphic,
or mutant alleles in a genome-wide manner [33,34,38].
These techniques, in combination with the comprehensive
deletion libraries available for both species [35,39], have
been used to provide an overview of the functional de-
pendencies within eukaryotic cells, and give insight
into both the function of individual genes and the
organization of biological systems [40-42]. Further-
more, cross species comparison has identified a high
conservation (19% to 29%) of SS/SL interactions between
orthologous gene pairs in Sc and Sp [33,34,41,42].
Here we surmised that complementary genetic ana-
lyses of specific MMR genes in the evolutionary distant
S. cerevisiae and S. pombe could be used to dissect the
function(s) of each individual factor. We further posited
that screening against non-essential gene deletions could
maximize the potential of identifying SS/SL interactions
with potential therapeutic utility. Moreover the identifi-
cation of Conserved Genetic Interactors (CGIs: SS/SL in
both yeasts) could then be tested as candidate drug
targets in MSI-positive CRC cell lines. An obvious poten-
tial limitation of this approach is the requirement for a
high degree of conservation between the yeast and human
orthologs. In this regard the MMR factors are particularly
well conserved across evolution, which extends to preserv-
ing the same repair functions [43]: thus CGIs for each
yeast gene might be expected to have strong predictive
power for their mammalian orthologs.
Methods
In situ mutagenesis
Constructs for de novo gene deletion were assembled by
PCR megapriming from budding or fission yeast genomic
DNA and plasmid templates [44,45]. The resulting prod-
ucts were transformed/targeted by homologous recombin-
ation in the desired budding or fission yeast backgrounds
and confirmed by sequencing and/or phenotypic analyses
as appropriate [46].
PEM2 (Pombe Epistatic Mapping) analyses in fission yeast
Genetic screening in fission yeast used the PEM-2 ap-
proach [34,47]. In brief, NAT-marked (encoding nour-
seothricin resistance) queries in the PEM-2 background
(p392; KFP171) were crossed to a library of 1,955 non-
essential gene deletions, with mating, haploid selection,
data acquisition, and analysis as previously. Specific
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ect mating, tetrad dissection and spot-testing. Pairwise
correlation coefficients (CCs) to examine any relation-
ship between genetic screens were calculated by the
CORREL function in Excel [42].
Approaches in saccharomyces cerevisiae
Many MMR factors participate in meiosis [48], such that
some genetic interactions in fission yeast could be the
result of a meiotic defect rather than manifesting during
mitotic growth. To avoid this possibility genetic inter-
actions in budding yeast were examined after direct
transformation, plasmid shuffling by 5-fluoroorotic acid
(5-FOA) selection, and spot-testing. In brief, specific dele-
tions (as KAN cassettes flanked by approximately 500 bp
of genomic sequence) were amplified from the relevant
heterozygous diploid library strain (Open Biosystems),
transformed to the appropriate msh2Δ or msh3Δ shuffle
strain (with each NAT-marked genomic deletion covered
by the relevant wild-type allele on a low-copy URA3
containing plasmid), and homologous-integration events
identified by PCR. Replicate clones were successively
grown on media containing uracil (to allow loss of the
URA3 plasmid) and 5-FOA (converted to a toxic me-
tabolite in the presence of a functional URA pathway,
thus isolating double deletion cells). Spot-testing was
then performed to evaluate the fitness of the double
deletion clones versus their single deletion parents.
Any sensitivity to genotoxins was investigated by spot-
ting onto solid media with various concentrations of
each agent: camptothecin (CPT) (5, 7.5, and 10 μM),
methyl methanesulfonate (MMS) (0.005%, 0.075%, and
0.01%), hydroxyurea (HU) (5 mM, 7.5 mM, and 10 mM),
or 5-fluorouracil (5-FU) (38 μM and 76 μM). Strains were
spotted as 10-fold serial dilutions onto the relevant plates
and growth examined at 48, 72, and 96 h.
Approaches in mammalian cells
Standard methods were used to examine any genetic
interactions in the MSH2-deficient human endometrial
cancer cell line HEC59 (MSH2−) and its isogenic chromo-
some 2-complemented counterpart (MSH2+) [49]. Trans-
fections with siRNAs (Dharmacon; sequences in Additional
file 1) and the TransIT-siQUEST (Mirus) reagent were
performed in six-well plates by specific optimization of
the manufacturer’s suggested conditions. Total RNA was
isolated by the RNeasy plus kit (Qiagen) 24 h after siRNA
transfection, cDNA synthesized with random hexamers
and the Superscript III reverse transcriptase (Invitrogen),
and specific transcript levels measured by qPCR (after
pre-amplification if required) [50]. SENP6 protein levels in
permeabilized cells 48 h after siRNA transfection were
measured by fluorescence cytometry after successive stain-
ing with monoclonal mouse anti-human SENP6 (NovusBiologicals) (or an isotype control antibody: eBioscience)
and anti-mouse IgG2a-PE (eBioscience) (Additional file 1:
Figure S1). Apoptosis in specific populations was quantified
by activated caspase 3. In brief, cells were trypsinized,
stained with LIVE/DEAD fixable violet (Invitrogen), fixed
with 2% paraformaldehyde, and permeabilized with 0.3%
saponin. Each sample was then successively stained with
rabbit anti-caspase 3 (Cell Signaling Technology) and goat
anti-rabbit IgG-Alexa488 (Molecular Probes), and analyzed
by fluorescence cytometry. DNA double strand break levels
in specific populations was quantified by γH2AX. In brief,
72 h after siRNA transfection/24 h after PARP inhibition
(20 μM olaparib), cells were permeabilized with Transcrip-
tion Factor Buffer (BD Pharmingen), successively stained
with rabbit anti-γH2AX (Cell Signaling Technologies) and
goat anti-rabbit IgG-Alexa488, and analyzed by fluores-
cence cytometry. To estimate clonogenic survival, cells
were re-plated 72 h after siRNA transfection/24 h after
PARP inhibition (5 μM olaparib). In brief, cells were col-
lected after each treatment (of triplicate wells), resuspended
in the same volume of media, diluted 1/500, and an equal
aliquot from each sample re-plated and incubated for
2 weeks. Cells were fixed with 2% paraformaldehyde,
stained with crystal violet, colonies counted, and the clo-
nogenic potential after each treatment of each population
expressed relative to the respective siNT-1 (no drug).
Results and discussion
For this study three specific MMR genes involved in mis-
match recognition (MSH2, MSH3, and MSH6, comprising
subunits of the MutSα and β heterodimers: Figure 1A)
were chosen for direct analysis. MSH3−/− mice have late
onset intestinal tumors and MSH3-deficiency modifies the
tumor spectrum of p53 mutant mice [10,51].MSH3 muta-
tions are rarely seen in HNPCC/LS, although frame-shifts
at repeat sequences within the gene are frequently de-
tected in MSI positive CRCs [2,52,53]. MSH2 is frequently
mutated in HNPCC/LS, while MSH6 mutations are more
rare (although MSH6, like MSH3, is also commonly
frame-shifted in MSI positive CRCs [52,54]). Thus the
specific genetic interactors of each gene could identify
novel therapeutic targets for these conditions. Compre-
hensive genetic interaction data for all three factors
would also be expected to distinguish the relationship of
MutSα and MutSβ with other repair pathways or biological
processes.
Genetic interaction profiling distinguishes fission yeast
MutSα and MutSβ
Appropriate deletion strains (for example, msh2Δ::NAT)
were mated to a library of 1,955 deletions (approximately
52% of the non-essential Sp genome [35]), and double-
mutant haploid daughters selected with the Pombe Epi-
static Mapper-2 (PEM-2) approach [34,47] (see Methods).
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by photography and image analysis) as a quantitative
readout to derive scores covering each negative genetic
interaction (< −2.5: SS/SL) [34,42]. Of note, the deletion
of msh3 leads to a modest increase in mutation rates
[55], while msh2Δ or msh6Δ each reduce the fidelity of
DNA replication >100-fold in S. pombe [56], S. cerevisiae
[55] and mammals [57]. The resulting accumulation of
secondary mutations had the potential to compromise our
genetic screening, so multiple independent clones of each
deletion were analyzed to obtain a high-quality dataset
(Figure 2A). To date we have screened 953 query alleles
against an array of 1,955 non-essential deletions and
comprehensive benchmarking confirms the value of this
resource: known SS/SL interactions are reproduced, and
protein-protein interactions are accurately predicted
[34,42]. Analysis of the msh2Δ, msh3Δ, and msh6Δ
replicates confirm these global trends, with their data
being highly correlated (Pearson correlation co-efficient
(CC) >0.4) indicating that individual SS/SL predictions are
highly reproducible (for example, Figure 2A and B).
The genetic interaction (GI) profile of a mutant allele
comprises its set of interacting partners, or in the case
of our quantitative screening, the set of scores for these
interactions (for example, Figure 2A). GI profiles have
been used to predict gene function with high confidence,
while the degree of similarity to other mutant profiles
can reveal how groups of gene products cooperate in
higher-level biological processes [34,42,60,61]. As an
example, Msh2 enters into heterodimeric complexes with
Msh3 and Msh6, so it might be expected that the set of
genetic interactions for msh2Δ would encompass those
observed on deletion of both its partners. Alternatively,
since MutSα (Msh2-Msh6) is sufficient for the majority of
fission yeast MMR [56], the genetic interactions for
msh2Δ and msh6Δ could have been very similar. To inves-
tigate this we compared the profile for each mshΔ within
our (953 × 1,955) dataset [42], with significant relatedness
considered a Pearson CC >0.3 [34,42,60]. In this approach
msh2Δ had no discernible relationship to msh6Δ, but was
instead highly correlated with msh3Δ (Figure 2B). We
considered that msh2 and msh3 may be genetically related
by their loss of function in a process other than MMR.
Budding yeast MutSβ also acts with the Rad1-Rad10
nuclease to remove non-complementary tails during
DNA DSB repair by homologous recombination [11]
(Figure 1A). We thus noted with interest that the GI
profiles of msh2 and msh3 were both highly correlated
with those of fml1 (Sc Mph1; ATP-dependent 3′ to 5′
DNA helicase, FANCM ortholog), rhp55 and rhp57 (both
RecA family ATPases), and rhp51 (Sc Rad51; RecA family
recombinase) (Figure 2B), all of which regulate DNA
double-strand break (DSB) repair by recombination [62,63].
Thus the similar GI profiles of fission yeast msh2Δ andmsh3Δ might be due to their shared role in recombina-
torial rather than mismatch repair [58,64,65].
Network analyses suggest that the average orthologous
gene has significantly more genetic interactions than
sequence orphans (that is, genes with no identifiable
orthologs in other species) [42]. The MSH genes are
highly conserved, yet msh6Δ showed an unexpectedly
low percentage of negative GIs relative to all profiles in
our (953 × 1,955) dataset (4.6% msh2Δ; 2.5% msh3Δ;
1.1% msh6Δ vs. 3.8% average [42]). This distinction
from the general trend suggested a limited cross-talk
between Msh6 and other pathways: this could be because
its protein product acts exclusively in MMR, although
such an interpretation is made with caution. In this study
genetic interactions were revealed by the specific read-out
of altered colony size on rich media. Repeating these ana-
lyses in the presence of genomic stress (for example,
genotoxin-induced damage) might uncover additional, or
an altered spectrum, of synthetic interactions [61,66], and
thus reveal more functional relationships for MutSα.
Identification of evolutionarily conserved GIs for msh2Δ/
msh3Δ in fission/budding yeasts
We next sought evolutionarily conserved genetic interac-
tions (CGIs) for fission and budding yeast msh2Δ/msh3Δ
to identify orthologous relationships of possible utility in
mammalian systems. Twenty-six candidates (25 one-
to-one orthologs and the paralogous pair mlp1/mlp2)
from the fission yeast SS/SL dataset (for example,
Figure 2A) were chosen for direct study by satisfying
three criteria: synthetic with both msh2Δ and msh3Δ;
identifiable Sc and human/mouse orthologs (or a limited
group of paralogs); and non-essential in both Sc and hu-
man/mouse, thus increasing their potential therapeutic
utility. Each mutant combination was created and exam-
ined for growth on rich-media and any additional sensitiv-
ity to genotoxins, which included 5-fluorouracil (5-FU).
This agent is a commonly used chemotherapeutic for
colorectal cancer, although MMR-deficient MSI-positive
tumors display resistance [12,13]: thus synthetic chemo-
sensitization in any double-mutant background would be
of particular interest.
Testing these 26 candidates identified seven orthologous
negative interactions, with a genotoxin-aggravating effect
on the double mutant observed in most cases (Figure 3).
This moderate number of CGIs for msh2/msh3 (7/25 or
approximately 28%) is consistent with recent studies inter-
rogating the conservation of global genetic interaction
trends across both yeasts [41,42]. The large-scale studies
had further noted that GIs within functionally related gene
pairs (such as those involved in the same pathway or
process) are more highly conserved across species than
those between seemingly unrelated gene pairs [41,42].
However the specific CGIs formsh2Δ andmsh3Δ (Figure 3)
Figure 2 (See legend on next page.)
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Figure 3 Direct testing identifies conserved orthologous relationships with MutSβ in fission and budding yeast. Negative interactions
from fission yeast were tested for orthologous conservation and potential synthetic chemo-sensitivity in budding yeast. msh2Δ- or msh3Δ-containing
strains were created by plasmid shuffling and spotted as serial 10-fold dilutions onto the indicated medium (see Methods). To facilitate
cross-comparison results are expressed by a color-code indicating the growth of each strain on a six-point scale relative to wild-type in each
condition (all after incubation at 30°C for 72 h). rad55Δ is a positive control for genotoxin sensitivity [74]. Hatch-bar, not tested; YPD,
non-selective media; CPT (5 μM); MMS (0.005%); HU (5 mM); 5-FU (Low dose, 38 μM); 5-FU (High dose, 76 μM).
(See figure on previous page.)
Figure 2 Genetic screening distinguishes the MutSβ complex in actively growing yeast. (A) The specific genetic interactions of fission
yeast msh2Δ and msh3Δ are similar and distinct from msh6Δ. NAT-marked deletions (for example, msh2Δ::NAT) were placed in the context of
1,955 non-essential fission yeast gene deletions and relative colony size used to derive scores covering each negative (≤ −2.5) genetic interaction
(see Methods). Shown are a representative set of 53 genetic relationships expressed by heat map (key below) and identified by their systematic
ID and standard Sp/Sc (if present) gene names. Blue, orthologous relationships also tested in budding yeast (see Figure 3). Red, Sp-specific orphans.
Given the high rate of replication-errors in MMR-gene mutants [56,58], multiple queries of each deletion were screened to obtain a high confidence
dataset. The independent accumulation of confounding secondary mutations may explain why the specific genetic interactors from this
study are not described in the available high-throughput datasets that relied on single deletion clones [33,40,59]. (B) Distribution plot of
Pearson correlation co-efficients (CCs) comparing the genetic interaction profiles of msh2Δ and msh3Δ within a (953 × 1,955) dataset. Red
dots indicate the CC of each genetic screen to a specific msh2Δ or msh3Δ query clone: shaded area highlights screens that would be classed
as significantly correlated (CC ≥0.2).
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Tco89, for example, is a subunit of the TORC1 complex
that regulates growth in response to nutrient availability
[67]; Sch9 is an AGC family protein kinase downstream of
TORC1 mediated regulation of ribosome biogenesis,
translation initiation and entry into G0 [68]; Nup60 is a
nucleoporin component of the nuclear pore complex [69]
and involved in gene tethering to the nuclear membrane;
Arp8 is an actin-related protein and subunit of chromatin
remodeling complexes [70]; and Mrt4 regulates mRNA
turnover and ribosome assembly [71]. Although the mo-
lecular basis for these genetic interactions is currently
unclear, their conservation across such evolutionary dis-
tance indicates functional importance and may reflect
the diverse pathways involved in genome maintenance.
The CGIs between msh2Δ/msh3Δ and tco89Δ, for ex-
ample, may reflect the sensitivity of MMR-deficient
colorectal cancer cells to mTOR inhibition by rapamy-
cin [72]. Likewise the CGIs with nup60Δ may be linkedFigure 4 Increased polysumoylation is lethal in msh2Δ fission yeast. (
msh2Δ. msh2Δ and ulp2Δ strains were mated, sporulated, tetrads dissected
depicts the sumoylation pathway. Fission yeast contains one gene encodin
proteases (Ulp1 and Ulp2). (C) msh2Δ is SL with ulp2Δ but neutral with ulp1Δ
viable spores observed/expected for each genotype is indicated (see also Add
but not pli1Δ, rescue the lethality of (msh2Δ/ulp2Δ). Strains were mated, spor
file 1: Figure S2C to E). Panel (E) depicts representative tetrads to demonstrateto the role of the (Nup60/Mlp1-2) nuclear pore complex
in maintaining SUMO-protease Ulp1 at the nuclear en-
velope to regulate the sumoylation of several proteins,
including DNA repair factors [73].
The group of CGIs common to msh2Δ and msh3Δ
contains two additional factors involved in protein sumoy-
lation: Ulp2 (Sc Ulp2) and Rrp1 (Sc Uls1) (Figures 2A
and 3). The Ulp2 peptidase deconjugates SUMO poly-
chains from proteins and plays a role in the recovery
from checkpoint arrest induced by DNA damage or
replication defects [75,76]. The Rrp1 ATPase regulates
the proteolytic control of sumoylated substrates and
the response to replication stress [77,78]. This cluster
of CGIs strongly suggested a ‘cross-talk’ between MutSβ
and the SUMO pathway. The (msh2Δ/ulp2Δ) interaction
is synthetic lethal in fission yeast (Figures 2 and 4A),
synthetic sick and aggravated by 5FU (a commonly used
chemotherapeutic agent) in budding yeast (Figure 3). We
thus chose to perform a more detailed genetic analysis ofA) Deletion of the Ulp2 SUMO-protease is synthetic lethal (SL) with
and genotypes determined ((ulp2Δ/msh2Δ) is boxed). (B) Schematic
g SUMO (Smt3), two E3-ligases (Pli1 and Nse2), and two SUMO
. Strains were mated, sporulated, and tetrads dissected. The number of
itional file 1: Figure S2A and B). (D, E) smt3Δ or nse2-SA (catalytic dead),
ulated, and the indicated number of tetrads dissected (see also Additional
the growth of each mutant combination.
Figure 5 (See legend on next page.)
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Figure 5 SENP6 knockdown induces a hyper-acute apoptotic response in MSH2-deficient human cells. (A-D) Efficient targeted knockdown of
SENP6 or SENP7 in MSH2-deficient HEC59 cells. In A, B mRNA was quantified by qPCR; in C, D SENP6 protein was detected by flow cytometry (see
Methods). Note specificity of SENP6 knockdown in response to siSENP6-C or siSENP6-1 [93], but not siSENP7 (pooled siSENP7-1 and siSENP7-2) or
non-targeted siNT-1. (E) SENP6 (but not SENP7) knockdown induces apoptosis in HEC59 cells (MSH2−) relative to an isogenic chromosome 2 complemented
population (MSH2+). Caspase 3+ cells were identified 48 h after siRNA transfection (see Methods), normalized to siNT-1 in each population, and significance
determined by unpaired t-test (ns, not significant; *, P <0.01). (F) PARP inhibition induces DNA DSBs (γH2AX+ [97]), and to a greater degree in MSH2− cells.
γH2AX+ cells were identified 72 h after siRNA transfection/24 h after PARP inhibition (20 μM olaparib; see Methods) and the significance of pairwise
comparisons determined by unpaired t-test: (1) P <10−4; (2) ns, not significant; (3) P <0.008; (4) P <0.002. Panels (F-H) use the same color key and
siSENP6-1 for SENP6 knockdown (previous studies suggest off-target effects are unlikely [93]). (G) MSH2− cells show reduced clonogenic survival
(see Methods) in response to SENP6 knockdown, PARP inhibition, or their combination. Any significance of indicated pairwise combinations
was determined by unpaired t-test: (1) P <0.02 (may be related to the additional copy of chromosome 2); (2) ns, not significant; (3) P <0.001; (4) P <0.01;
(5) P <0.0007; (6) P <0.03; (7) P <0.01. (H) (MSH2/SENP6) deficient cells exhibit a hyper-apoptotic response to PARP inhibition. Activated caspase 3 levels
72 h after siRNA transfection/24 h after PARP inhibition (20 μM olaparib) were quantified by flow cytometry and normalized to siNT-1 (no drug). Any
significance of various pairwise combinations was determined by unpaired t-test: (1) P <10−5; (2) P <10−6 (also seen with MSH3− [98]); (3) P <10−7.
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orthologous relationship in mammalian cells.
Increased polysumoylation is toxic to msh2-deficient
yeast cells
Sumoylation is a reversible post-translational modification
that controls the localization, function, interaction, and
stability of a large number of proteins, including many in-
volved in transcription, replication, and the DNA damage
response [79]. Indeed recent studies highlight the import-
ance of a reversible SUMO-response to preserve genome
integrity [80,81]. Fission yeast encodes one form of SUMO
(Smt3 aka. Pmt3), two SUMO E3-ligases (Pli1 and Nse2),
and two SUMO proteases (Ulp1 and Ulp2; Figure 4B).
Pli1 catalyzes the majority of cellular sumoylation, while
Nse2 targets a limited number of substrates during DNA
repair [82,83]. For deconjugation, Ulp1 removes single
SUMO modifications and is required for efficient cell
cycle progression [84,85]. Ulp2, in contrast, edits poly-
SUMO chains, desumoylates the majority of factors ac-
tivated in response to DNA damage or DNA replication
defects, and regulates the recovery from checkpoint
arrest [75,76,86,87].
On direct testing the SL interaction of (msh2Δ/ulp2Δ)
is not observed with (msh2Δ/ulp1Δ) (compare Figure 4A
and C), indicating that the accumulation of specific
sumoylated substrates is toxic to fission yeast cells that
also lack an Msh2-mediated repair pathway. This may be
because Msh2 is absolutely required to resolve lesions that
occur at increased levels in the context of ulp2Δ [88].
Alternatively cells lacking Msh2 might accumulate un-
resolved DNA damage and induce a poly-sumoylated
substrate (or substrates) that cannot be metabolized in
the absence of Ulp2, blocking cell cycle progression
[87]. The identity of such substrates is currently un-
known, though many central players in replication and
recombination (for example, Rad52, PCNA, RPA) are
sumoylated in response to DNA damage, and this is
important for their repair function [79]. To investigatethis further we tried to create triple mutants containing
msh2Δ, ulp2Δ and a mutation in either SUMO itself
(pmt3Δ) or one of its E3-ligases (pli1Δ, or the nse2-SA
allele that lacks SUMO ligase activity but retains the
essential function for Nse2 in chromosome maintenance
[89]). Following tetrad dissection we obtained the
triple mutant combinations (msh2Δ/ulp2Δ/pmt3Δ) and
(msh2Δ/ulp2Δ/nse2-SA), but not (msh2Δ/ulp2Δ/pli1Δ)
(Figure 4D and E and Additional file 1: Figure S2). This
clearly demonstrates that msh2Δ is lethal in combination
with a deletion of Ulp2, the primary protease to desumoy-
late DNA damage response proteins [87,88], but this can
be rescued by inactivating the primary ligase for sumoyla-
tion in response to DNA damage [82,83].
Conservation of the GI between MSH2 and the
deSumoylation pathway in mammals
We next sought to examine if the CGI between budding
and fission yeast msh2 and ulp2 predicted an orthologous
relationship in human cells. Humans encode four SUMO
proteins (SUMO1-4 with relatedness: SUMO1, SUMO2/3,
unconjugated SUMO4) and six SUMO-specific cysteine
proteases (SENPs). Of these, SENPs 1/2/3/5 are most
closely related to Ulp1 and specifically deconjugate single
SUMO1/2/3, while SENPs 6/7 resemble Ulp2 and edit
polysumo chains with a clear preference for SUMO2/3
[90-92]. A limited literature discriminates the distinct
roles of mammalian SENP6 and SENP7 [93-95]. How-
ever both are expressed in a variety of tissues including
the colonic epithelium [90] and thus might be active in
MMR-deficient colorectal cancer cells.
To investigate any relationship between human MSH2,
SENP6, and SENP7 we used siRNA to efficiently
knockdown each SUMO protease in HEC59 cells (an
Msh2-deficient endometrial cancer line) and their
isogenic chromosome 2-complemented MSH2 proficient
counterparts (Figure 5A to D). SENP6 knockdown re-
sulted in significantly increased apoptosis in MSH2-
deficient relative to MSH2-proficient cells (Figure 5E),
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in budding and fission yeasts (Figures 2A and 3). Inter-
estingly SENP7 knockdown had no effect (Figure 5E).
This SUMO protease was recently shown to interact
with chromatin remodelers and contribute to chromatin
relaxation during DNA repair by homologous recombin-
ation [94-96]. However our results indicate that the effect
of SENP7 knockdown on recombinational repair does not
lead to increased apoptosis in MSH2-deficient cells.
Human SENP6 maintains the hypo-sumoylation of
RPA70, and thus regulates homologous recombination-
mediated repair during S-phase [93]. This finding allied
with our results in yeast may imply that the conserved
synthetic interaction between MSH2/msh2 and SENP6/
ulp2 is due to the combined loss of MutSβ- and RPA-
mediated DNA DSB repair. Consistent with this notion,
the addition of Olaparib (a PARP inhibitor that induces
the accumulation of ssDNA breaks that ultimately result in
DSBs during replication [99-101]) rendered a significantly
greater number of γH2AX+ cells in the (MSH2/SENP6)
deficient population versus singly-deficient controls
(Figure 5F). This is accompanied by the reduced clono-
genic survival of MSH2− cells in response to SENP6
knockdown, olaparib treatment, or their combination
(Figure 5F). In isolation this synthetic interaction provides
no direct mechanistic insight, but further analyses
showed that the (MSH2/SENP6) deficient population
also displayed a hyper-acute apoptotic response to ola-
parib (Figure 5H). It appears likely that (MSH2/SENP6)
deficient cells are incapable of resolving the genomic le-
sions induced by PARP-inhibition, with apoptosis be-
coming a preferred response. Olaparib is currently in
phase II clinical trials for the treatment of BRCA1/2-
dependent breast and ovarian cancers [102-104]. Our
findings suggest that it may also enhance the efficacy of
strategies that target components of DSB repair path-
ways in MSH2-deficient tumors.
Conclusions
This study describes the identification of conserved
genetic interactions between the MutSβ subunits and
orthologous genes encoding diverse biological functions in
two evolutionarily distant yeast species. It further demon-
strates that unexpected genetic relationships could be
exploited to treat loss-of-function disorders. In the specific
example presented, the synthetic interaction of (MSH2/
SENP6) deficiency enhanced by PARP inhibitors indicates
that a significant proportion of MMR-deficient cancers
could be targeted via their loss of function in MutSβ-
mediated recombinatorial, rather than mismatch, repair
[10] (Figure 1A). Ongoing studies have established the
central role of reversible sumoylation in an efficient DNA
damage response, suggesting that the SUMO pathwaymight contain novel druggable targets for anticancer ther-
apeutics [79,105]. In this work we suggest that targeting
specific SUMO proteases may be highly effective in the
treatment of MMR-deficient cancers. The recent develop-
ment of SENP6-specific small molecule inhibitors
[106] could prove invaluable for further experiments in
this regard.Additional file
Additional file 1: Additional information is available with the online
version of this paper. This single file contains all siRNA sequences, data
regarding the specificity of anti-SENP6 (Figure S1) and detailed tetrad data
analyzing the genetic relationship between msh2Δ and deletions of the
fission yeast protein sumoylation machinery (Figure S2).
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